King Star Capital
6
96M
5
0.17
4
- Areas of investment
Summary
We also calculated 1 valuable employee in our database.
Deals in the range of more than 100 millions dollars are the general things for fund. The fund is generally included in 2-6 deals every year. The important activity for fund was in 2018. Comparing to the other companies, this King Star Capital performs on 21 percentage points more the average number of lead investments. The top amount of exits for fund were in 2019.
Among the most popular portfolio startups of the fund, we may highlight CStone Pharmaceuticals, MabSpace Biosciences, Gracell Biotechnologies. The fund has exact preference in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Pharmaceutical.
The typical case for the fund is to invest in rounds with 6 participants. Despite the King Star Capital, startups are often financed by WuXi Healthcare Ventures, F-Prime Capital, Oriza Seed Capital (Oriza Yuandian). The meaningful sponsors for the fund in investment in the same round are Sequoia Capital China, Lilly Asia Ventures, YF Capital (Yunfeng Capital). In the next rounds fund is usually obtained by 6 Dimensions Capital.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 0
- Exits
- 4
- Follow on index
- 0.17
- Investments by industry
- Medical (5)
- Biotechnology (5)
- Health Care (4)
- Health Diagnostics (1)
- Pharmaceutical (1) Show 3 more
- Investments by region
-
- China (6)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Group Appearance index
- 1.00
- Avg. company exit year
- 8
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Ronovo Surgical | 14 Jun 2024 | Health Care, Robotics, Medical Device | Early Stage Venture | 46M | Shanghai, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.